Cash of €252.0 million compares with a six-month net loss of €31.0 million and €29,917 thousand used in operating activities. The release gives no efficacy figures for either of the two drugs.
AgomAb priced 12,500,000 ADSs at $16.00 for $200,000,000 and expects about $181 million in net proceeds. Its lead drug has shown only safety results in a Phase 2a Crohn's trial, and the prospectus reports an accumulated loss of €164.3 million.
AgomAb Therapeutics filed to sell American depositary shares and list them on Nasdaq as AGMB. The price range and share count are blank, and the company has a Phase 2a Crohn's trial whose published results were on safety only.
Questions about AgomAb Therapeutics NV
When did AgomAb Therapeutics NV go public?
Our latest story on this, dated Aug 6, 2026: "AgomAb Therapeutics NV reports €252.0 million cash after $208 million IPO". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of AgomAb Therapeutics NV?
AgomAb Therapeutics NV trades under the ticker AGMB on NASDAQ.
Where is AgomAb Therapeutics NV listed?
AgomAb Therapeutics NV is listed on NASDAQ.
What is the SEC CIK of AgomAb Therapeutics NV?
The SEC Central Index Key (CIK) for AgomAb Therapeutics NV is 2020932. Its filings are on SEC EDGAR.
How many shares does AgomAb Therapeutics NV have outstanding?
34,167,168 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-23.
Which country or territory is AgomAb Therapeutics NV listed under?
Our directory records AgomAb Therapeutics NV under Belgium.
What does AgomAb Therapeutics NV do?
Our directory classifies AgomAb Therapeutics NV as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of AgomAb Therapeutics NV?
The ISIN recorded for AgomAb Therapeutics NV is US00860C1027.
Does aibio.space cover AgomAb Therapeutics NV?
aibio.space lists AgomAb Therapeutics NV among 2,820 public biotech companies and publishes its news here as stories appear.
Where is AgomAb Therapeutics NV incorporated?
SEC records list its state or country of incorporation as C9.
What is the latest AgomAb Therapeutics NV (AGMB) stock news?
Our latest story on AgomAb Therapeutics NV, dated Aug 6, 2026: "AgomAb Therapeutics NV reports €252.0 million cash after $208 million IPO". Cash of €252.0 million compares with a six-month net loss of €31.0 million and €29,917 thousand used in operating activities. The release gives no efficacy figures for either of the two drugs. Source.
What is AgomAb Therapeutics NV's latest stock offering or financing news?
Our latest financing story, dated Aug 6, 2026: "AgomAb Therapeutics NV reports €252.0 million cash after $208 million IPO". Cash of €252.0 million compares with a six-month net loss of €31.0 million and €29,917 thousand used in operating activities. The release gives no efficacy figures for either of the two drugs. Source.
Who were the underwriters or placement agents on AgomAb Therapeutics NV's offering?
From our story: J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen are the underwriters named on the prospectus. Source.
How long will AgomAb Therapeutics NV's cash last?
From our story of Aug 6, 2026: The company expects that cash to fund operating expenses and capital spending into the first half of 2029. Source.
Is AgomAb Therapeutics NV a smaller reporting company?
SEC records list AgomAb Therapeutics NV's filer category as: Non-accelerated filer<br>Emerging growth company.
Investor discussion: AgomAb Therapeutics NV
Members talk about AgomAb Therapeutics NV (AGMB). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at AgomAb Therapeutics NV, newest first. Each line links the filing it comes from.
Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. Source
Financings
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Financings
Filed a registration statement for a share offering. SEC Form F-1. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:AGMB on TradingView.
SEC filings and registration
SEC name
AgomAb Therapeutics NV
CIK
2020932
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
AGMB (Nasdaq)
State or country of incorporation
C9
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Emerging growth company
Business address
POSTHOFLEI 1/6, ANTWERPEN, 2600
Phone
32 3 302 35 30
Shares outstanding
34,167,168 as of 2025-12-31 (20-F filed 2026-04-23)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
AgomAb Therapeutics NV is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AGMB, recorded under Belgium. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio